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 32 
ABSTRACT 33 
Background:  Vitamin D is critical for skeletal health and is increasingly associated with 34 
other pathologies encompassing gastrointestinal, immunological, psychological effects. A 35 
significant proportion of the population exhibit suboptimal levels of vitamin D, particularly in 36 
Northern latitudes in winter. Supplementation is advocated, but few data are available on 37 
achievable or typical rates of change. There has been considerable interest in the potential use 38 
of sublingual sprays for delivery of nutrient supplements, but data on efficacy remains sparse. 39 
Methods:  A randomised, placebo-controlled, 3-arm parallel design study was conducted in 40 
healthy volunteers (n=75) to compare the rate of change of vitamin D status in response to 41 
vitamin D3 (3000IU/day) supplementation in capsule and sublingual spray preparations over 42 
a six-week period between January and April 2017.  Blood 25(OH)D concentrations were 43 
measured after day 0, 3, 7, 14, 21 and 42 days of supplementation with 3000IU per diem.   44 
Results:  Baseline measurements show 25(OH)D deficiency (<30nmol/l), insufficiency (31-45 
46nmol/l) and sufficiency (>50mmol/l) in 14.9%, 44.6% and 40.5% of the participants 46 
respectively. There was a significant elevation in blood concentrations of 25(OH)D in both of 47 
the treatment arms (capsule p=0.003, spray p=0.001) compared to control.  The capsule and 48 
spray were equally efficacious. The rate of change ranged from 0.69-3.93 (capsule) and 0.64-49 
3.34 (spray) nmol/L day with average change in blood 25(OH)D levels of 2 nmol/l/day. Rates 50 
followed a simple normal distribution in the study population (ks= 0.94 and 0.82 for capsule 51 
and spray respectively). The data suggest that rates of change are higher in individuals with 52 
lower levels of 25(OH)D.   53 
Conclusions:  A sublingual vitamin D spray is an effective mode of delivery for 54 
supplementation in a healthy population.  The data provide reference values and ranges for 55 
the rate of change of 25(OH)D for nutrikinetic analyses.  56 
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 62 
INTRODUCTION 63 
Vitamin D is essential for the homeostasis of calcium and phosphate and well known for its 64 
role in the development and maintenance of bone health 
1
 . Once vitamin D has been ingested 65 
or synthesised via sunlight exposure it requires activation in the liver to form 25 66 
hydroxyvitamin D (25(OH)D) and in the kidney to form 1,25 dihydroxyvitamin D (1,25 67 
(OH)2D
2
.  25(OH)D is the most abundant circulating form in the human body and is used to 68 
determine vitamin D status.  25(OH)D levels can be defined as; sufficient (50nmol/L), 69 
insufficient (30-<5049 nmol/L) of deficient (<30 nmol/L)
3, 4
 . There is limited  research on 70 
rates of repletion; one paper reports amounts for maintenance of blood 25(OH)D at 50nmol/L 71 
requires around 11-weeks of dosing at 1000 IU vitamin D per day 
5
.   Hypovitaminosis is 72 
evident worldwide and is a major public health concern 
6
 leading to advocacy for 73 
supplementation in at-risk groups. Research has also shown African Americans may require a 74 
higher dose of vitamin D supplementation to reach optimal serum 25(OH)D concentrations 75 
compared to the Caucasian participants 
7
, perhaps as a result of lower baseline 25(OH)D 76 
levels in this population 
8
.  It is also known that serum 25(OH)D levels is inversely associated 77 
with body fat mass 
9
. 78 
Supplementation has classically been with capsule preparations, but sublingual sprays are 79 
increasingly available. There are few data available on the relative efficacy of each type of 80 
preparation on rate of change in circulating levels. Dose response studies using capsular 81 
delivery of vitamin D supplementation 
10-12
 have shown evidence of efficiency in increasing 82 
serum 25(OH)D levels which  plateau and begin to decrease. 83 
This study aimed to measure and compare the rate of change of circulating vitamin D in 84 
response to capsular or sub-lingual delivery of a daily vitamin D supplement.  85 
 86 
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 88 
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METHODS 91 
Study design 92 
This was a 6-week double blind, placebo-controlled 3-arm parallel design study.   The 93 
participants attended three visits at The Medical School of The University of Sheffield.  The 94 
initial visit included anthropometrics, issue of first batch of blood test kits and completion of 95 
a first self-test blood sample.  The second visit occurred approximately two weeks after the 96 
initial visit for issue of further test kits and to support participant retention in the trial.  The 97 
final visit required participants to return their preparation bottles and answer five questions 98 
regarding the study.   99 
Sample size and randomisation 100 
There were no data upon which to base a power calculation. 75 healthy male and female 101 
participants were recruited between January 2017 and February 2017 and were randomly 102 
assigned to one of three arms: (i) active capsules and placebo spray (n= 25); (ii) active spray 103 
and placebo capsules (n= 25); (iii) double placebo (n= 25). Participants were randomised 104 
according to a computer generated random sequence using block randomisation with a block 105 
size of 9, with randomisation undertaken by an independent outside source.  The allocation 106 
sequence was not available to any member of the team until databases had been completed 107 
and locked. 108 
Participants 109 
The University of Sheffield Research Ethics Committee granted ethical approval for this 110 
study (Ref: 011865).  Participants were recruited via poster advertisements at the University 111 
of Sheffield and through a student volunteer email list.  Inclusion criteria required 112 
participants to be fit and healthy and aged between 18-50 years. Participants who reported 113 
any micronutrient supplement use (vitamin D, multi-vitamin, fish oils), recent or upcoming 114 
sunny holiday, pregnant or lactating, history of gastrointestinal disease, BMI >30, diabetes, 115 
>50 years of age were excluded.   A total of 124 potential participants were approached, of 116 
which 49 were excluded:28 did not meet inclusion criteria and 21 had no further contact after 117 
initial consultation.   118 
Participant  measures 119 
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The concentration of 25(OH)D in the blood was assessed by blood sample using a finger-120 
prick blood spot kits at 0,3,7,14,21 and 42 days of supplementation. Blood spots were 121 
analysed by liquid chromatography tandem mass spectrometry (Waters TQD and Acquity 122 
UPLC) for total blood 25(OH)D (25(OH)D2 and 25(OH)D3). LC-MS was undertaken by City 123 
Assays, Department of Pathology, Birmingham Sandwell Hospitals NHS Trust. Previous 124 
work has shown that this method is comparable to other commercial assays with intra and 125 
interassay coefficients of <10% and <11% respectively 
13-15
.  Anthropometric measurements 126 
included; height, weight, BMI, and body fat percentage.  Body fat and weight were measured 127 
using Tanita BC-543 
16
.  Skin tone was assessed by the researcher using 1= Caucasian, 2 = 128 
Asian, 3 = Black.   129 
Qualitative opinion of capsules and sprays were assessed via exit questionnaire.  Participants 130 
were asked if they had a preference between preparations  131 
Did you have a preference between the two preparations? If so which one?” 132 
 Answers were categorised as; yes, the spray, yes, the capsule and no preference.    133 
Intervention 134 
The vitamin D3 and corresponding placebos were manufactured by Cultech Ltd., Port Talbot, 135 
UK and provided by Better You Ltd, Barnsley, UK.  Preparations of vitamin D3 and 136 
corresponding placebos were provided as 15 ml sprays and capsule. Each capsule and spray 137 
contained 3000 IU (75 µg) of vitamin D3 per dose.  The content of the spray and the capsule 138 
from the manufacturer was prepared to 97.5 µg/dose in order to maintain shelf life and to 139 
guarantee dose. Volunteers were instructed to ingest one capsule per day with water and one 140 
spray orally per day for 6 weeks.  Compliance was measured by weighing the spray bottles 141 
and counting the remaining capsules at the end of the study.  86% and 96.4% of participants 142 
reached 100% compliance with the spray and capsules respectively. 143 
Adverse events 144 
Two participants reported that small blisters formed on cheek and tongue after the study 145 
began.  One participant stopped using the preparations for the duration of the study.  The 146 
second participant continued to use the preparations throughout the intervention. 147 
 148 
 149 
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Statistical analyses 150 
The data on vitamin D status was held by a third party until all other data entry was complete, 151 
spreadsheets were then merged and analysis was undertaken at a group level with blinding to 152 
group identity.  Statistical analysis was performed using the Statistical Package for the Social 153 
Sciences (SPSS) (IBM SPSS Statistics for Windows, V.23; IBM Corp.).  Percentage change 154 
in 25(OH)D from baseline was determined by analysis of variance (ANOVA) with 155 
Boneferroni correction.  Pearsons correlations for rate of change in 25(OH)D per day was 156 
performed.  Change in 25(OH)D over 6 time points were analysed by repeated measures 157 
ANOVA (there was a high failure rate in assessments of 25(OH)D at day 42, leading to the 158 
exclusion of this time points data from the main analysis).  Comparisons between percentage 159 
change in 25(OH)D from baseline in deplete and replete participants were assessed by Mann-160 
Whitney U Test.  Two-tailed tests were used in all analyses with the significance value of 161 
<0.05.   162 
  163 
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RESULTS 164 
Baseline demographics are shown in Table 1 and a CONSORT is supplied in the online 165 
supplement.  The three arms were similar in numbers, age, BMI, body fat, height, weight, 166 
skin tone, sex and baseline blood 25(OH)D concentrations.  Baseline blood 25(OH)D 167 
concentration showed 59% of participants had insufficient/deficient vitamin D status 168 
(<50nmol/L).  169 
Intention-to-treat analysis was used to evaluate the 5 time points up to day 21.   Kolmogorov170 
Smirnov test (ks) indicates that the rate of change of 25(OH)D for both treatment arms follow 171 
a normal distribution (p = 0.200). Raw data are available in the online supplementary bundle.  172 
Blood 25(OH)D concentration analysed across the time course in all three trial arms by 173 
ANOVA showed a significant improvement in 25(OH)D status in those receiving vitamin D 174 
compared to placebo. Post hoc analyses revealed significant differences between each of the  175 
active treatments and the placebo (capsules p= 0.003, spray p= 0.001), but no difference 176 
between the active preparations at any time point (Fig 1A). As there are few available data on 177 
the rates of change of ingested vitamin D, we assessed the inter-individual and inter-178 
preparation difference as change in whole blood nmol/L/d (Fig1Bi-ii). Whilst there was a 179 
range of rates in each dataset, assessment of the distribution of rate showed a monotonic 180 
normal distribution for both preparations with similar peak rates (Fig 1Biii-iv). Independent t-181 
test was performed and found no significant difference between mean rates of change for 182 
capsule and spray.  A Mann Whitney U Test was used to compare differences between 183 
deplete and replete participants within the treatment arms (replete data was not normally 184 
distributed with a KS score of p = 0.001). There was a significant difference (p=0.001) in the 185 
percentage change of 25(OH)D between the replete and deplete from baseline to day 21.  186 
In order to investigate a potential homeostatic mechanism for 25(OH)D status, we 187 
investigated the relationship between 25(OH)D status and rate of change (Fig 1Bv-vi). We 188 
observed inverse relationships between baseline whole blood 25(OH)D and rates of change 189 
over 21 days using Pearsons correlation for both the spray (r
2
 =0.255, p= 0.012) and capsule 190 
(r
2
 =0.351, p=0.003).  191 
In an exit interview about preference for either the spray or capsule for delivery, 60% 192 
preferred spray, 24% capsules and 16% did not express a preference.  193 
 194 
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DISCUSSION  196 
Advocacy for vitamin D supplementation for some subpopulations, interest in its use, 197 
availability of over-the-counter preparations, and lack of information on the factors 198 
predisposing to development of excessive levels collectively identify a need for research on 199 
comparative efficacy of preparations and the saturability of uptake. This study used two 200 
commonly available vitamin D preparations; the widely used capsules and a more novel 201 
sublingual spray to investigate these factors. 202 
Our findings show that a sublingual spray is equally effective at raising blood 25(OH)D 203 
concentrations with no significant difference between rate of change compared to capsules in 204 
this study population.  The study participants reported a preference for the sublingual spray, 205 
and this study demonstrates that this delivery platform is of comparable efficacy. Sublingual 206 
sprays may be particularly advantageous in people with pre-existing malabsorption 207 
conditions or swallowing problems. Our analysis shows for the first time the likely rate of 208 
change in 25(OH)D and the range of these rates, albeit in a relatively small, healthy sample. 209 
The monotonicity of our rate distribution suggests a limited spread of rates with no 210 
suggestions of outliers or subpopulations, however the relatively homogenous profile of the 211 
study population, whilst an advantage for this pilot exploration, is a limitation in terms of the 212 
prediction of rates in other groups (older adults, different ethnicities).  A recent review 
17
 213 
does offer suggested optimal supplementation rates to achieve adequate serum 25(OH)D 214 
levels (75 nmol/L) in regional, population and age-specific groups.    215 
These data also suggest that baseline 25(OH)D status may influence the rate of change, as a 216 
correlation between baseline status and change exhibited a moderate inverse relationship, 217 
furthermore the circulating  25(OH)D concentrations started to level off towards the end of 218 
the intervention. This is in agreement with previous research by Lips et al.  2001 who 219 
reported that change in serum 25OHD in response to 6 months vitamin D supplementation 220 
was dependent on baseline vitamin D status, with the greatest change observed in people with 221 
the lowest baseline vitamin D 
18
.  Our research complements the previous work by 222 
undertaking an intervention over a shorter timeframe with sampling along the timecourse, 223 
demonstrating a baseline status-dependent response to the intervention and the possibility of a 224 
plateau effect. The mechanistic basis of this is unclear, and it is notable that both delivery 225 
platforms exhibit this effect, implying control in both enteric and transbuccal absorption. 226 
Future work may address the strength of this inferred relationship more thoroughly and 227 
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identify implied control mechanisms.    This study had no data from which a power 228 
calculation could be determined, however the data presented herein may prove useful for the 229 
design of prospective intervention studies.   230 
A limitation to this study is that we cannot show definitive absorption of the sublingual 231 
supplement.  However, sublingual routes of drug delivery are established in pharmacokinetic 232 
studies 
19, 20
.  Recent research presented by Satia and colleagues found superior sublingual 233 
absorption compared to capsules in patients with malabsorption issues 
21
.  Participants were 234 
given clear guidelines on how to use the spray. Further studies should assess, 25(OH)D, and 235 
1,25(OH)D levels in localized tissues with the use of labelled D3.   236 
CONCLUSIONS 237 
In summary, we have shown the capsule and sublingual spray are equally effective at 238 
delivery of a vitamin D supplement.  There was an overwhelming preference (64%) for the 239 
spray over capsules for mode of supplement delivery. Rate of change, reported for the first 240 
time, exhibits a monotonic distribution in this population. This study saw a reduction in 241 
25(OH)D levels as blood 25(OH)D concentrations increased over 21 days in both 242 
preparations. This suggests the oral spray has the same known mechanism as the capsule for 243 
slower conversions of vitamin D3 when concentrations are higher 
22
 . These data illustrate the 244 
need for further studies to explore rate of change across mixed population groups, especially 245 
those identified as high risk.   246 
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FIGURE LEGENDS 342 
Figure 1.  Efficacy and rates of vitamin D uptake with differing delivery platforms. 343 
Panel A shows change in vitamin D circulating levels over time in each of the three study 344 
arms, presented as absolute levels (panel Ai) or relative to baseline (Panel Aii). Panel B 345 
shows rates of uptake comparing spray (left column) with capsules (right column). Panels Bi 346 
and Bii show ladder plots for individuals in each arm of the trial plotting difference in 347 
vitamin D between day 0 and day 21 (the abscissa for uptake, based on Panel A). Rates were 348 
derived as nmol/L/day and binned into 5nmol bins (Panels Biii and Biv). KS tests showed the 349 
data were normally distributed (capsules p=0.200, spray p=0.200). Finally, the rates for each 350 
individual were correlated with the baseline serum concentration for that individual (Panels 351 
Bv and Bvi). The r
2
 and p values for correlations are indicated.  352 
Table 1.  Demographic characteristics and mean serum vitamin D at baseline and exit.  353 
The data are presented in means±SD.  Baseline characteristics are given along with exit 354 
serum 25(OH)D.  Significant values are p >0.005.  A one-way ANOVA was used to compare 355 
means at baseline and exit for serum 25(OH)D. 356 
 357 
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 365 
 366 
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 371 
 372 
 373 
 374 
375 
 376 
25 25 25 75  
14 10 15 39 0.326 
22.9(±4.82) 22.4(±2.72) 21.7(±3.05) 22.4(±3.65) 0.504
2 23.6(±2.95) 22.7(±2.72) 23.8(±2.59) 23.4(±2.77) 0.294
23.4(±7.75) 19.1(±5.91) 23.7(±7.65) 22.1(±737) 0.043
171.3(±7.54) 173.5(±10.20) 170.0(±8.35) 171.6(±8.77) 0.357
69.6(±10.71) 68.6(±12.77) 69.0(±11.32) 69.1(±11.48) 0.958
22/2/1 24/0/1 25/0/0 71/2/2 0.268
50.7(±19.73) 45.6(±21.30) 54.9(±27.84) 50.5(±23.24) 0.381 
91.35(±19.78) 55.62(±34.40) 95.78(±28.03) 81.13(±33.02) 0.001 
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